Merck KGaA

Archer will develop and pursue regulatory approval for a companion diagnostic that will help find patients who may benefit from one of Merck's drug candidates.

Merck will use Definiens' web-based collaboration software platform alongside Definiens' image-analysis technologies for biomarker quantification.

The German drugmaker plans to advance the NSCLC treatment in parallel with tissue-based and liquid biopsy companion assays that can identify best responders.

The reagents involved in the deal improve the specificity and fidelity of PCR reactions.

The two companies have signed a new master collaboration agreement under which HTG will  develop custom assays for use in earlier stages of Merck's drug development process.

The tests were developed as part of a partnership with Merck KGaA, one of the manufacturers of the anti-EGFR therapy Erbitux.

Guardant is providing its Guardant 360 CDx test for a clinical trial of Merck's small molecule, c-Met kinase inhibitor called tepotinib.

The companies are aiming to identify treatment-response biomarker signatures in patients with advanced melanoma.

The company said its proxy-CRISPR tool can facilitate precise gene editing and eliminates the need for genetic engineering of naturally occurring CRISPR proteins.

The moves underscore a growing belief in industry and academia that the cell-derived vesicles could be the biomarker of choice for next-generation tests and therapies.

Pages

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.